Dr. Jordi Monés
Dr. Jordi Monés is an M.D., Ph.D., Ophthalmologist, Macula and Vitreorretinal Specialist and Researcher. Since 2007, he has been the Director of the Institut de la Màcula (accredited site of the network of excellence in research, European Vision Institute) and the Director, principal investigator and one of the founder governors of the Barcelona Macula Foundation: Research for Vision since 2011. Member of COMB 22.838.
He is an Elected Member of the AMD and Member of the Steering Committee of the International Multicenter Clinical Trials Proxima A and Proxima B on Geographic Atrophy (Roche) and Member of the Steering Committee International Multicenter Clinical Trials Brighter and Crystal (Novartis).
He was also the Coordinator of Ophthalmology at the Centro Médico Teknon from 2010 until 2015. Dr. Monés has also been a Member of the Board of Directors of Futbol Club Barcelona and the head of the Medical and Performance Department from 2003 to 2005 and 2010 to 2015.
Dr. Monés is the head commissioner for promoting the FC Barcelona Universitas project. He earned his Medicine and Surgery degree and his PhD cum laude in Medicine and Surgery at the Universitat de Barcelona. He specialized in Ophthalmology at the Centro de Oftalmología Barraquer (Universitat Autònoma de Barcelona). He obtained his Retina Specialist degree at the Massachusetts Eye and Ear Infirmary at Harvard University, and at the Hospital San José at the Monterrey Institute of Technology and Higher Education (ITSM).
His research fields of particular interest are macular diseases, choroidal neovascularization, macular degeneration, antiangiogenic therapy, anti-PDGF therapy, geographic atrophy, retinal degeneration, retinal transplants, stems cells, gene therapy, macular edema, and vitreoretinal and macular surgery.
As the founder and Medical Director of the Barcelona Macula Foundation: Research for Vision (BMF) he is dedicated to fighting blindness, supporting and conducting research in retinal diseases that currently have no treatment. At the BMF, all our resources and endeavors are directed so that macular and retinal diseases do not prevent our patients continuing with their daily activities as normally as possible. The Foundation was born after 20 years of treating patients day by day and sharing their suffering about serious sight loss combined with clinical trial performance. This experience led to our commitment to research, design and perform studies at pre-clinical level in order to move to Phase I clinical trials for orphan macular and retinal degeneration as soon as possible.
Through collaboration and partnerships with other centers, universities and companies, BMF promotes research and innovation projects that enable us to develop technologies and treatments that may be applied in clinical practice and may benefit our patients as soon as possible. Retina transplants, stem cell translational therapy, optogenetics, prosthesis, new laser applications, new drugs, minimally invasive surgery, imaging and adaptive optics, etc., are the lines guiding our present research projects.
For the last twenty years he has been a researcher in most of the international multicentre clinical trials for the treatment of age-related macular degeneration (AMD). A reference researcher as Principal Investigator in macular degeneration for the last 15 years (TAP, VIP; VER, VISION, RETAANE, GENEVA, AART, EXCITE, BEVASIRANIB, RANEOVASC, etc.)
Currently he is conducting clinical and pre-clinical trials in phases I, II, III and IV and Investigator-driven trials (13 trials during 2014). For instance: CHROMA, FOVISTA E10030-02, M-13-056, MACBETH, TREND, FOVISTA OPH 1003, BRIGHTER, CRYSTAL, MPL4DRY, MPL4DRUSEN, ORAL OMEGA 3 DRY/GA, etc.
Dr. Monés is also participating in four major European Union (EU) projects performed by several agencies from different countries. These projects have received funding from the European Union’s Horizon 2020 Programme.
- Exploring the combined role of genetic and non-genetic factors for developing AMD: A systems level analysis of disease subgroups, risk factors, and pathways (EYE RISK). This project is a major European Union project performed by 11 partner agencies in 7 countries and it has received funding from Horizon 2020 Research and Innovation Actions.
- ADVANCE(CAT): Accelerator for the development of advance therapies in Catalonia (COMRDI15-1-0013). The principal aim of the ADVANCE(CAT) project is the development of medicinal products for human use, from preclinical phases to their clinical application, based on genes (gene therapy), cells (cell therapy) and tissue (tissue engineering).
- Integrated use of second harmonic generation (SHG) microscopy to image corneal collagen fibrils and adaptive optics scanning laser ophthalmoscopy (AOSLO) to image the photoreceptors (LITE). This project is being developed in collaboration with the ICFO (Institute of Photonic Sciences) together with 4 more partner agencies. It is co-financed by Acció (the Agency for Business Competitiveness) and the European Union through the Seventh Framework Programme of Research and Technological Development.s.
- Innovative PROcurement for Visual Impaired People (PRO4VIP). This project is a major European Union (EU) project performed by 12 partner agencies in 5 countries.
He has published widely in scientific journals and specialist books and has given more than 300 talks at international congresses and meetings. He also participates in the organizing committee and scientific committee of several drug workshops and international conferences.
Furthermore, Dr Monés is a Member of the Steering Committee at the International Multicenter Clinical Trials Proxima A and Proxima B on Geographic Atrophy (Roche) and a Member of the Steering Committee at the International Multicenter Clinical Trials Brighter and Crystal (Novartis), and a member of several International Scientific Advisory Boards, such as AMD International Alliance, ERAB Allergan (Irvine, California USA), REONET Novartis (Basel, Switzerland), Ophthotech (Princeton, NY, USA), Notalvision (Tel Aviv, Israel), Eylea Bayer Schering Pharma (Basel, Switzerland).
Finally, he is a member of 12 scientific societies, being the only retina specialist in the Spanish state to become a member of the four most important retina associations of restricted admission: the Macula Society, the Retina Society, the Club Jules Gonin and the American Society of Retina Specialists.